FOXM1过表达与pT1期非肌层浸润性膀胱癌不良结局及膀胱灌注治疗反应相关
该回顾性研究分析了296例pT1期非肌层浸润性膀胱癌患者的组织标本,采用定量RT-PCR检测FOXM1等mRNA表达。结果显示FOXM1过表达与不良临床病理特征及更差的PFS和CSS相关,并可预测患者对膀胱灌注治疗的反应。
要点
- FOXM1过表达与pT1期NMIBC的不良临床病理特征及更差预后相关。
- 高FOXM1表达患者可从丝裂霉素C膀胱灌注化疗中获益。
- FOXM1可识别管腔亚型中预后更差的亚组患者。
核心结论
- 高FOXM1表达与不良临床病理特征及更差结局相关,并可预测pT1期NMIBC患者对膀胱灌注治疗的反应。
研究设计与样本
- 回顾性分析296例接受保留膀胱治疗的pT1期NMIBC患者的临床数据及石蜡包埋组织。
- 采用单步定量RT-PCR检测FOXM1、MKI67、KRT20和KRT5的mRNA表达。
主要发现
- FOXM1 mRNA表达与MKI67显著相关(ρ=0.6530,P<0.001),与KRT20正相关(ρ=0.2113,P<0.001)。
- FOXM1表达与伴发原位癌(P=0.05)、多灶性肿瘤(P=0.005)及WHO 1973分级3级(P<0.001)相关。
- FOXM1过表达与更差PFS(P=0.028)和CSS(P=0.015)相关。
- FOXM1过表达是CSS的预测风险因素(HR 1.61 [1.13-2.34],L-R chi-squared: 7.19,P=0.007)。
- 在管腔亚型中,FOXM1过表达识别出RFS(P=0.017)、PFS(P<0.001)和CSS(P=0.015)更差的亚组。
关键数值与推荐
- 低FOXM1表达患者无论是否接受灌注治疗结局均较好,高FOXM1表达患者从丝裂霉素C膀胱灌注化疗中获益。
临床怎么用
- FOXM1表达检测可能有助于pT1期NMIBC的风险分层及灌注治疗决策。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the role of forkhead box protein M1 (FOXM1) mRNA expression and its prognostic value in stage pT1 non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Clinical data and formalin-fixed paraffin-embedded tissues from transurethral resection of the bladder from patients with stage pT1 NMIBC, treated with an organ-preserving approach, were analysed retrospectively. Total RNA was isolated using commercial RNA extraction kits, and mRNA expression of FOXM1, MKI67, KRT20 and KRT5 was measured by single-step quantitative RT-PCR using RNA-specific TaqMan Assays. Statistical analysis was performed using Spearman's Rho, Wilcoxon or Kruskal-Wallis tests, Kaplan-Meier estimates of recurrence-free (RFS), progression-free (PFS) and cancer-specific survival (CSS) and Cox regression analysis. RESULTS: Data from 296 patients (79.4% men, median age 72 years) were available for the final evaluation. Spearman correlation analysis showed that mRNA expression of FOXM1 was significantly correlated with MKI67 (ρ: 0.6530, P < 0.001) and with the luminal subtype, reflected by the positive correlation with KRT20 (ρ: 0.2113, P < 0.001). Furthermore, there was also a strong correlation of FOXM1 expression with adverse clinical and pathological variables, such as concomitant carcinoma in situ (P = 0.05), multifocal tumours (P = 0.005) and World Health Organization 1973 grade 3 disease (P < 0.001). Kaplan-Meier analysis showed overexpression of FOMX1 to be associated with worse PFS (P = 0.028) and worse CSS (P = 0.015). FOXM1 overexpression was also shown to be a predictive risk factor for CSS (hazard ratio 1.61 [1.13-2.34], L-R chi-squared: 7.19, P = 0.007). FOXM1 overexpression identified a subgroup of patients within the luminal subtype with worse RFS (P = 0.017), PFS (P < 0.001) and CSS (P = 0.015). Patients with low FOXM1 expression had better outcomes, irrespective of instillation therapy, whereas patients with high FOXM1 expression benefitted from intravesical chemotherapy with mitomycin C. CONCLUSION: High FOXM1 expression was associated with adverse clinical and pathological features and worse outcomes, and predicted response to intravesical instillation therapy in patients with stage pT1 NMIBC.
引用
- Breyer J, Wirtz RM, Erben P, et al. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. BJU Int. 2018. PMID: 30120861. doi:10.1111/bju.14525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。